A number of studies indicate that glutamatergic N-methyl-D-aspartate (NMDA) neurotransmission is disturbed in schizophrenia partly based on the findings that NMDA receptor antagonists such as phencyclidine (PCP) can reproduce a schizophrenia-like syndrome in both humans and rodents. This study investigated whether repeated administration of low doses of PCP can induce cognitive dysfunctions in mice at doses which produce no sensorimotor disturbances. In addition, the effects on cognition were related to the expression of two genes, Arc and spinophilin, which have been related to neuronal plasticity and learning. Adult male C57Bl/6J mice received daily s.c. doses of PCP (0.5-2.0 mg/kg) or saline for 7 d. Testing was performed 24 h after the last day of treatment. Only the 2.0 mg/kg PCP dose produced a consistent impairment in spatial learning and working memory performed in the water-maze task without any apparent sensorimotor deficits. Importantly, the 2.0 mg/kg PCP dose produced no impairment in a non-spatial learning paradigm in the water-maze task. PCP treatment altered Arc mRNA levels in the hippocampus and retrosplenial agranular cortex while leaving the striatum and prefrontal cortex unaffected. The mRNA expression of spinophilin was down-regulated in striatum by repeated PCP treatment. These results demonstrate that repeated treatment with low doses of PCP in mice can produce specific cognitive deficits which are associated with alterations in gene expression in brain regions that appear to play a role in the pathophysiology of schizophrenia. These results suggest that the low-dose PCP model may have significant potential in characterizing the behavioural and molecular mechanisms underlying cognitive deficits seen in schizophrenia patients.
Introduction
Schizophrenia is a serious mental disorder with a complex symptomatology. Symptoms of schizophrenia are usually divided into three categories, including positive and negative symptoms as well as cognitive dysfunctions (Andreasen, 1996) . The neurocognitive impairments seen in schizophrenia are believed, by some investigators, to represent a core feature of the disorder (Meltzer and McGurk, 1999) but it has remained unclear whether the mechanisms behind the cognitive impairments are the same as the ones responsible for the disorder. For several decades the symptoms of schizophrenia have focused on the dopamine hyperactivity hypothesis (Carlsson and Lindqvist, 1963) . During the past two decades, more and more evidence have emerged for a possible hypofunction of the N-methyl-D-aspartate (NMDA)-glutamate transmission system in schizophrenia (Olney et al., 1999) . This hypothesis is partly based on the observation that NMDA receptor (NMDAR) antagonists such as phencyclidine (PCP) and ketamine reproduce a schizophrenia-like psychosis in humans including positive symptoms, negative symptoms as well as cognitive dysfunctions (Javitt and Zukin, 1991 ; Krystal et al., 1994 ; Luby et al., 1959 ; Malhotra et al., 1997) The psychotomimetic effects of NMDAR antagonists in human volunteers and their ability to exacerbate psychotic symptoms in schizophrenia patients have led to the hypothesis that glutamatergic NMDA neurotransmission is disturbed in schizophrenia (Sawa and Snyder, 2002) .
In recent years there have been intensive efforts to develop animal models of schizophrenia based on the use of NMDAR antagonists such as PCP, ketamine and MK-801 (dizocilpine) (Javitt and Zukin, 1991 ; Jentsch and Roth, 1999) . Studies in both rodents and monkeys have shown that both acute and repeated PCP administration can produce a behavioural syndrome, which in many ways resembles both positive and negative schizophrenia symptoms (Jentsch and Roth, 1999) . The locomotor-activating effects of NMDAR antagonists have been linked to positive symptoms (Castellani and Adams, 1981 ; Jackson, et al., 1994 ; Kitaichi et al., 1994 ; Ogren and Goldstein, 1994) , while the effect on immobilization in the forced swim test and the effect on social withdrawal have been related to negative symptoms (Corbett et al., 1995 ; Sams-Dodd, 1998a ,b, 1999 . Disruption of prepulse inhibition by NMDAR antagonists such as PCP has been related to deficits in sensorimotor gating (Bakshi et al., 1994 ; Varty et al., 1999) . In addition, acute and chronic administration of NMDAR antagonists in adult rats has also been shown to disturb performance in spatial working and reference memory tasks (Adams and Moghaddam, 1998 ; Kesner and Dakis, 1997 ; Kesner et al., 1993 ; Stefani and Moghaddam, 2002) . Jentsch and Roth (1999) have proposed that the behavioural effects of chronic, rather than acute, PCP exposure to monkeys and rodents may better represent some aspects of schizophrenia. Neuroanatomical and neurochemical alterations have been observed after withdrawal from repeated PCP treatment in the rat, which mimic changes observed in schizophrenia patients (Jentsch and Roth, 1999 ; Olney et al., 1999) . However, repeated PCP treatment is also associated with profound neurotoxic insult in many areas of the rat brain including the entorhinal, cingulate and retrosplenial cortices as well as the hippocampus (Olney et al., 1999) . Thus, both acute and repeated PCP administration can produce neurochemical, neuroanatomical and behavioural alterations, which can confound measures of cognitive function.
To solve this problem, we have investigated a mouse model in which it is possible to distinguish between the acute effects of PCP on spatial learning from its effect on sensorimotor function. Thus, the effect of repeated low doses of PCP administration was investigated with the drug on board at testing of cognitive functions. By using a low repeated dose of PCP (0.5 mg/kg), it was possible to obtain impairment in spatial learning and memory without apparent sensorimotor defects (Beraki et al., 2008) . However, even doses of 1 and 2 mg/kg of acute PCP affected sensorimotor functions, which confounded measures of cognition. The impairing effect of 0.5 mg/ kg PCP was blocked by treatment with clozapine (an ' atypical ' antipsychotic drug), but not with haloperidol (a 'typical ' antipsychotic drug) (Beraki et al., 2008) .
The aim of the present study was to use a 'repeated dose-withdrawal design ', i.e. the animals are tested at a time when the drug is present at very low brain concentrations, which do not block NMDARs (Proksch et al., 2000) . For that purpose, PCP was given in the 0.5-2 mg/kg dose range for 7 d and the spatial learning and memory tests were initiated 24 h after the final PCP dose. Another important aim was to investigate whether this procedure will affect both hippocampal reference memory and non-hippocampal memory functions (i.e. working memory), to model the multiple cognitive impairments seen in schizophrenia patients. To investigate potential molecular mechanisms underlying the behavioural effects of PCP on cognition, we also examined the mRNA expression of Arc (activity-regulated cytoskeletonassociated gene) and spinophilin by the use of in-situ hybridization in brain regions associated with both schizophrenia and cognition. These two transcription factors have been implicated in synaptic plasticity and learning and memory (Daberkow et al., 2007 ; Sarrouilhe et al., 2006 ; Steward et al., 1998 ; Tzingounis and Nicoll, 2006 ; Wu et al., 2008) .
Materials and methods

Subjects
Experiments were performed in adult male C57BL/6J mice (aged 3 months ; Scanbur, Sollentuna, Sweden). Mice were kept under standard laboratory conditions with free access to food pellets and tap water up to the time of the experiment. They were housed 4-5 per cage in standard transparent type III Makrolon 1 cages All studies were approved by the Ethics Board of Animal Experimentation of Northern Stockholm.
Treatment with PCP
Animals received daily subcutaneous (s.c.) injections (10:30 hours) of either vehicle (0.9 % NaCl ; 4.0 ml/kg) or PCP [1-(1-phenylcyclohexyl) piperidine hydrochloride ; Sigma, St Louis, MO, USA] in the dose range 0.5-2.0 mg/kg for a period of 7 d before the beginning of the experiments. Volume of injection was 4 ml/kg.
Experiment 1 : Long-term memory task in the water-maze
Spatial learning and memory were examined using a circular water tank (180 cm diameter, 45 cm height), surrounded by several extra-maze cues. The water tank was filled with tap water (22-23 xC) and a circular escape platform of 15 cm in diameter was placed 1.0 cm below the water line. The behaviour of the animals in the water-maze was monitored by a CCD camera (JVC, Tokyo, Japan) located above the centre of the water tank connected to the WaterMaze Software (Edinburgh, UK) which was used to monitor several parameters of the animals' behaviour (Beraki et al., 2005) .
Training sessions
During training the hidden escape platform was located in the north-east quadrant. The mice were trained for 5 consecutive days (four trials per day). The maximum trial duration to locate the invisible escape platform was 90 s, if they failed, they were guided to the platform, e.g. by the operator's hand. The animals were allowed to spend 10 s on the platform before being removed to a cage to dry. The inter-trial time was 10 min to avoid hypothermia.
Retention test
The retention test was performed 3 h after the last training trial with the platform removed from the pool (probe trail). The mouse was released into the water tank from a position opposite to the quadrant where the platform had been located during training sessions. Mice were allowed to swim for a 60-s period to find the location of the former platform position.
Experiment 2 : Non-spatial training task in the water-maze
The procedure for non-spatial training is similar to the acquisition procedure described above. Non-spatial training was examined at 24 h, 3 d and 5 d after the last PCP injection. Non-spatial training was performed (four trials per day) using a visible platform onto which a black flag was attached. The platform was placed 0.5 cm above the water line. During this procedure the water tank was surrounded with an opaque curtain to block all access of external visual cues. The mice were tested in the water-maze from randomized starting points and different platform positions. During both the spatial and non-spatial training, the following parameters were analysed : latency to escape to the platform (s), swim distance (cm) and average swim speed (cm/s). In the retention test the following parameters were analysed : percentage of time spent in the platform associated quadrant, number of crossings of the former platform position and latency (measured in seconds), to locate the previous position of the platform.
Experiment 3 : Accelerating rotarod performance
Motor coordination and balance were tested using an accelerating rotarod (Ugo Basile, Comerio, Italy). The rotarod test was performed by placing a mouse on a rotating drum and measuring the time each animal was able to maintain its balance walking on top of the rod. The speed of the rotarod accelerated from 4 to 40 rpm over a 5-min period. Mice were trained before and after treatment. Mice were given three trials with a maximum time of 300 s and a 15-min inter-trial test interval. The average of these three trials was used for the analysis. Motor coordination and balance were examined at 24 h, 3 d and 5 d after the last PCP injection.
Experiment 4 : Working-memory task in the water-maze
Working memory was examined in the water-maze using an invisible escape platform submerged in the water. In this procedure, the animals have to process and remember the information of the platform position for a short time, which is important for performance on a specific day. This information becomes irrelevant the next day because the platform is now placed in a new location. The mice were placed gently in the water-maze facing the wall and allowed a maximum of 60 s to locate the invisible escape platform. If they failed to do so, they were guided to the platform by the experimenter. The animals were allowed to spend 10 s on the platform before beginning of the next trial. Two trials per day were run over a 6-d period and the inter-trial interval was 15 s.
The position of the invisible platform was changed between each day of testing but it remained in the same position during the two trials on a given day. A different starting position was used on each trial, and different series of starting positions were used between days. Importantly, the distance between starting positions and platform position in these two trials was kept constant. Working memory was evaluated by the difference between escape latency and swim distance from trial 1 (when the location of the platform was unknown) to trial 2. During each trial, the mouse escape latency, swim distance and swim speed were analysed.
Experiment 5 : In-situ hybridization
RNA probe synthesis
In-situ hybridization with riboprobes was performed to detect the expression of transcripts encoding Arc and spinophilin. For Arc, we used a probe that has been previously described (Samaha et al., 2004) . For spinophilin, a new subclone was prepared by amplifying a unique region of spinophilin (AF016252, 2454-2938) from a rat brain cDNA library. The amplified cDNA fragment was subcloned into a pCR 1 II-TOPO vector (Invitrogen, Lidingö , Sweden), and confirmed by nucleotide sequencing. Linearized subclones were used to synthesize [ 35 S]UTP-labelled riboprobes. In-vitro transcription was carried out using the MAXIscript TM SP6/T7 kit (Applied Biosystems, Uppsala, Sweden) and [a 35 -S]UTP (SJ603, 20 mCi/ml ; GE Healthcare, Uppsala, Sweden) according to the manufacturer's instructions. The transcripts were purified using NucAway TM spin columns (Applied Biosystems).
Hybridization
Expression of Arc and spinophilin mRNAs in different brain regions was investigated using the in-situ hybridization technique. Brains were rapidly dissected and frozen on dry ice. Coronal sections (14 mm) of the above areas were prepared on a cryostat and stored at x80 xC until use. The in-situ hybridization was performed as follows. The frozen tissue sections were fixed for 10 min in cold 4 % paraformaldehyde in 0.1 M sodium phosphate buffer (PBS) (pH 7.4). After washing with PBS for 5 min, the sections were rinsed in DEPC-H 2 O (5 min) and deproteinated with 0.1 M HCl for 5 min. The sections were then rinsed twice with PBS (3 min each) and placed into 0.25 % acetic anhydride in 0.1 M triethanolamine (pH 8.0) for 20 min at room temperature ; washed twice in PBS (3 min each) and dehydrated at 70 %, 80 % and 100 % (2 min each). Sections were air dried and prehybridized [50 % deionized formamide (pH 5), 50 mM Tris-HCl (pH 7.6), 25 mM EDTA (pH 8.0), 20 mM NaCl, 0.25 mg/ml yeast tRNA, 2.5rDenhardt's solution] for 4 h at 55 xC. After draining off the prehybridization buffer, sections were hybridized overnight (14-16 h) in a humidified chamber at 55 xC. For hybridization, labelled probes were diluted to a final concentration of 1.0r10
6 cpm/200 ml in a solution containing 50 % deionized formamide (pH 5), 0.3 M NaCl, 20 mM Tris-HCl (pH 7.6), 5 mM EDTA (pH 8.0), 10 mM PBS, 0.2 mM dithiothreitol, 0.5 mg/ml yeast tRNA, 0.1 mg/ ml poly-A-RNA, 10 % dextran sulfate, 1rDenhardt's solution. After hybridization, the slides were rinsed in 1rstandard saline citrate (SSC), 0.01 % SDS (15 min) ; 1rSSC, 0.01 % SDS (30 min) ; 50 % formamide/ 0.5rSSC (1 h) ; 1rSSC, 0.01 % SDS (15 min) at 55 xC with continuous shaking. The sections were then treated with 1 mg/ml RNase A (Roche, Bromma, Sweden) in RNase buffer [0.5 M NaCl, 10 mM Tris-HCl, 5 mM EDTA (pH 8.0)] for 1 h at 37 xC. After two additional washes in 1rSSC, 0.01 % SDS for 30 min, the sections were dehydrated in ascending alcohol series and air dried. Sections were placed against b-Max film (VWR, Stockholm, Sweden) and stored at room temperature for 3-5 d. Films were developed in D19 developer for 2 min and in 1 : 5 dilution of Amfix fixative for 5 min. Non-specific hybridization was determined by incubating sections with the respective [
35 S]UTP-labelled sense cRNA probe for the above cDNA under identical conditions to that of the antisense RNA probe.
Quantification
Films were scanned with an Epson Perfection 4990 scanner as greyscale film, using 300 pixels and saved as high-quality JPEGs. Optical density values were quantified using appropriate software (NIH Image J version 1.29, U.S. National Institutes of Health, Bethesda, MD, USA). A 14 C step standard (GE Healthcare) was included to calibrate optical density readings and convert measured values into nCi/g. Optical density measurements were taken from two adjacent sections per animal and region of interest. A mean value was then generated for each region of interest to yield one data-point per animal for statistical analysis. All comparisons between groups were made on sections hybridized together, under identical conditions and exposed for the same time of period to b-Max film (VWR).
Statistical analyses
The results from the spatial long-term learning task were analysed with a repeated-measures two-way analysis of variance (ANOVA) (with drug and time as between-subject factors), followed, when appropriate, by Fisher's protected least significant difference test (Fisher's PLSD test). The working-memory task was analysed using a two-way ANOVA that considered the trial (1, 2) as a within-subject factor and treatment as a between-subject factor. Results obtained during the probe trial of the water-maze and rotarod were analysed using one-way ANOVA (StatView 5.0.1, SAS Institute, Cary, NC, USA). Statistical analysis of mRNA expression was performed using oneway ANOVA and individual comparisons were made using Bonferroni-Dunn tests. For all analyses, significance was assigned at the p<0.05 level. All data are presented as means¡S.E.M.
Results
Experiment 1 : Long-term memory task in the water-maze Training in the water-maze started 24 h after the last injection of saline or PCP. Two-way repeatedmeasures ANOVA revealed a significant treatment effect (F 3,27 =4.9, p<0.01. Figure 1a) . Post-hoc analysis of the escape latency with Fisher's PLSD test showed a significant increase in escape latency on days 3-5 in the 1.0 and 2.0 mg/kg PCP-treated groups (p<0.01) compared to both saline-and 0.5 mg/kg PCP-treated groups. In addition, there was a significant treatment effect with regard to swim distance (F 3,27 =3.1, p<0.05, Figure 1b) , with a significant increase in swim distance in both 1.0 and 2.0 mg/kg PCP-treated groups (p<0.01) compared to both saline and 0.5 mg/kg PCPtreated groups. There were no overall differences between the PCP-treated and control animals in swim speed during training (F 3,27 =1.2, p>0.05, Figure 1c ). In conclusion, the control mice run concurrently with the PCP-treated groups performed well in the water-maze task with a gradual decrease in the latency to find the hidden platform. In contrast, PCP produced a dosedependent impairment in water-maze performance with no apparent changes in motor performances (swim speed) during acquisition.
The results from retention (probe) trial are presented in Figure 2 . There was a significant (F 3,27 =4.3, p<0.05, Figure 2a ) increase in latency to navigate to the former platform position. The increased latency of 2.0 mg/kg PCP-treated mice to navigate to the former platform position differed significantly from saline-treated (p<0.01) mice and from the two other PCP-treated groups (0.5 and 1.0 mg/kg, p<0.05) (see Figure 2a) . The 2.0 mg/kg PCP-treated mice had also significantly (F 3,27 =3.2, p<0.05) fewer platform crossings (p<0.01) than the saline-and PCP-(0.5 and 1.0 mg/kg) treated groups (see Figure 2b ). These two measurements suggest that mice treated with the 2.0 mg/kg PCP dose failed to show a clear spatial preference for the former platform position. However, analysis of quadrant preference failed to show any differences between the saline-and PCP-treated groups due to the lack of target preference of the group. This finding is probably due to the low persistence of these mice in searching for the target quadrant. Based on the above finding the 2.0 mg/kg PCP dose was selected for all the subsequent studies given that this dose was able to impair spatial learning and memory without altering motor performance. Therefore, the following experiments investigated whether repeated administration of 2.0 mg/kg PCP could produce effects on non-spatial training, motor behaviour and spatial working memory.
Experiment 2 : Non-spatial training task in the water-maze Non-spatial training was examined at 24 h, 3 d and 5 d after the last PCP (2 mg/kg) injection (see Figure 3a -c). All animals were found to navigate to the visible platform without any problem. The statistical analyses revealed no significant differences in escape latency 24 h (F 1,14 =0.03, p>0.05, Figure 3a) , 3 d (F 1,14 =0.02, p>0.05, Figure 3b ) and 5 d (F 1,14 =0.3, p>0.05, Figure  2c ). With regard to swim distance there was no significant treatment effect 24 h (F 1,14 =0.01, p>0.05), 3 d (F 1,14 =0.01, p>0.05) and 5 d (F 1,14 =0.001, p>0.05). Analyses revealed no significant differences in swim speed at 24 h (F 1,14 =0.6, p>0.05), 3 d (F 1,14 =1.5, p>0.05) and 5 d (F 1,14 =2.5, p>0.05) between the PCPtreated animals and controls analysed using ANOVAs.
Experiment 3 : Accelerating rotarod performance
Motor coordination and skill learning were evaluated before treatment, and 24 h, 3 d and 5 d after the last day of PCP (2 mg/kg) injection. There was no significant group different before treatment (F 1,14 =0.02, p>0.05). Analysis showed no significant treatment effect after 24 h (F 1,14 =0.001, p>0.05, Figure 4a ), 3 d (F 1,14 =0.1, p>0.05, Figure 4b ) and 5 d (F 1,14 =0.01, p>0.05, Figure 4c ) in average time spent walking on the top of the rotarod after the last day of treatment.
Experiment 4 : Working-memory task in the water-maze
The critical measure of working memory is the improvement of escape latency from trial 1 (when the location of the platform is unknown) to trial 2. During the working-memory task, the interval between trials 1 and 2 was 15 s over 6 d testing. Saline-treated mice reduced escape latency between trials 1 and 2 across the 6 d testing. ANOVA of the mean escape latency revealed a significant effect of trial (F 1,14 =9.5, p<0.01, Figure 5a ). In addition, there was a treatmentrtrial interaction (F 1,14 =7.0, p<0.01). The trial effect was due to a significant improvement in escape latency from trial 1 to trial 2 which was observed in saline-treated mice (p<0.01), but not in the 2 mg/kg PCP-treated animals. A similar analysis was conducted with regard to swim distance and swim speed showing that there was a significant effect of trial in swim distance (F 1,14 =9.0, p<0.01, Figure 5b ) but not in swim speed (F 1,14 =0.14, p>0.05, Figure 5c ). Analysis of the mean swim distance revealed that saline-treated mice displayed a saving in swim distance from trial 1 to trial 2 (p<0.01).
Experiment 5 : Effects of PCP on gene expression
To investigate potential molecular mechanisms underlying the effects of PCP on cognition, we examined the mRNA expression of Arc and spinophilin, two genes that have been implicated in synaptic plasticity, and learning and memory (Daberkow et al., 2007 ; Sarrouilhe et al., 2006 ; Steward et al., 1998 ; Tzingounis and Nicoll, 2006 ; Wu et al., 2008) by means of in-situ hybridization. Twenty-four hours after the last treatment with PCP, Arc and spinophilin mRNA expression levels were investigated in prefrontal cortex, striatum, hippocampus and retrosplenial cortex. These brain regions were selected because they appear to play a role in the pathophysiology of schizophrenia (average over six trials per session, n=8 per group). Saline-treated mice (-%-) showed significant decrease in escape latency to find the hidden platform in trial 2 compared to the PCP-treated mice (-&-) which did not show significant improvement. (Sawa and Snyder, 2002) , and they have also been linked to the psychotomimetic action of PCP (Olney et al., 1999) . The specificity of the signals obtained with in-situ hybridization was confirmed using sense probes. Background levels were very low in all sections analysed from the selected brain areas. A representative section is shown in Figures 6 and 7 . Labelled structures are indicated and abbreviated according to the stereotaxic atlas of Paxinos and Franklin (2001) . Arc mRNA expression was found to be significantly up-regulated (F 1,11 =17.6, p<0.01 ; see Table 1 and Figure 6 ) in the CA1 region of the dorsal hippocampus in PCP-treated mice compared to saline-treated mice. The apparent increase in the CA1 of the ventral hippocampus in the PCP-treated mice failed to reach significance (p=0.06). PCP also significantly (F 1,11 =5.8, p<0.05, see Table 1 ) increased Arc mRNA expression in the agranular retrosplenial cortex. However, PCP treatment significantly reduced (F 1,13 =8.1, p<0 .05, see Table 1 and Figure 7 ) spinophilin mRNA expression in the striatum. No other significant changes in Arc or spinophilin mRNA expression were observed.
Discussion
General aspects
The main finding of this study is that repeated treatment with a low dose of PCP produces workingmemory and spatial-memory deficits in mice without any evidence for sensorimotor deficits. The impairing effects on cognition were found to be associated with alterations in genes involved in synaptic plasticity and learning, Arc and spinophilin, in brain areas associated with schizophrenia. Thus, the low dose PCP treatment preferentially changed gene expression of Arc in the limbic cortex circuitry, prefrontal cortex and dorsal hippocampus while the expression of spinophilin was seen preferentially in the basal ganglia.
Effects of PCP treatment on spatial learning and memory
The selection of the dose of PCP is critical for studying the performance in different cognitive tasks when the acute effect of PCP is examined. Dependent on the dose, acute PCP treatment can be associated with increased locomotor activity, sensorimotor disturbances, ataxia and neurological dysfunction (Sturgeon et al., 1982) , which could alter performance in the watermaze task. Previous results in the water-maze have shown that acute PCP treatment can impair learning and memory but it has been difficult to dissociate the effects of NMDAR blockade from sensorimotor disturbances, which confound measures of learning and memory (Ahlander et al., 1999 ; Cain et al., 1996) . The present study has demonstrated that repeated treatment with PCP can disrupt the spatial learning and acquisition of both working-memory and referencememory tasks. This impairment is found at doses of 1 and 2 mg/kg, which did not produce any apparent changes in motor functions as measured in swim speed and performance in the rotarod test. In addition, the PCP treatment failed to produce any apparent sensorimotor, motivational or visual disturbances as examined in the cued platform task. Moreover, the behavioural effects by repeated PCP are probably not due to neuropathological damages, i.e. neuronal vacuolization in the retrosplenial cortex seen after repeated administration of high doses of PCP to rats (Olney et al., 1989 (Olney et al., , 1999 . Thus, the repeated dose of PCP (2 mg/kg, s.c.) used in this study is lower than the Table 1.) range of PCP doses causing the pathomorphological neurotoxic syndrome in the rat (Ellison and Switzer, 1993 ; Olney et al., 1999) . Studies at the light microscopic level also failed to show any neurotoxical changes after repeated PCP (2 mg/kg) administration (S. Beraki, R. Diaz-Heijtz, S. O. Ö gren, unpublished data) .
In the present study, the animals were examined 24 h after the final dose of saline or PCP. In a previous study, PCP-treated animals were already impaired in spatial learning at the 0.5 mg/kg dose when the drug was given 15 min before training and thus, on board at testing (Beraki et al., 2008) . This indicates that a y4-fold higher dose of PCP is required to produce a spatial learning deficit when the animals are tested in the 'withdrawal ' state. This supports the hypothesis that the effects of PCP are probably not related to the presence of the compound in the brain at the time of testing which is consistent with the short half-life of PCP in rodents (Proksch et al., 2000) .
In view of the multiple neurocognitive dysfunctions in schizophrenia, it is notable that repeated PCP treatment impairs both the reference-memory and the working-memory task. Working-memory deficits, (For more detailed information on mRNA levels see Table 1. ) which are related to prefrontal cortex function, have been demonstrated in schizophrenia (Park and Holzman, 1992) . Schizophrenia patients also show memory deficits related to hippocampal abnormalities (Boyer et al., 2007) , a brain region implicated in spatial learning in both animals and human (Morris and Frey, 1997 ; Scoville and Milner, 2000 ; Squire and Zola-Morgan, 1991) . Compared to most previous studies, the 2 mg/kg PCP dose impairing both the spatial-memory and working-memory task is very low (Morris et al., 2005 ; Podhorna and Didriksen, 2005 ). An important factor in the analysis of the long-term action of PCP on cognition is the time of testing after drug withdrawal, which differs markedly. A study of object recognition in mice reported learning impairments 24 h after the last treatment of PCP (10 mg/kg.d for 5 d) (Mandillo et al., 2003) . In another study in mice, PCP treatment for 10 d (10 mg/kg.d, with 3 d withdrawal) showed also a long-term deficit in the object recognition task (Hashimoto et al., 2005) . These studies indicate that PCP can produce a long-term effect on memory functions (Morris et al., 2005 ; Podhorna and Didriksen, 2005) . However, results in the literature are still controversial since studies in the rat and mouse with high PCP doses have failed to impair working-memory functions (Li et al., 2003 ; Stefani and Moghaddam, 2002) .
Effects of PCP on the expression of Arc and spinophilin
To the best of our knowledge, this is the first study to investigate the mRNA expression of the immediate early gene, Arc after repeated low doses of PCP, in brain regions implicated in schizophrenia. Arc is expressed in glutamatergic neurons of the hippocampus and neocortex (Steward and Worley, 2001) , and it is rapidly induced by different forms of neuronal activity, including long-term potentiation (LTP), pharmacological stimulation, and behavioural stimulation (Fosnaugh et al., 1995 ; Guzowski et al., 1999 ; Lyford et al., 1995 ; Steward et al., 1998) . The most striking characteristic of Arc is that its mRNA is transported to dendrites and it is accumulated in the region of the dendritic tree where the inducing stimuli arrived (Steward et al., 1998) . Although the function of Arc is still unclear, it is believed to play a pivotal role in synaptic plasticity and learning and memory (see Introduction). For instance, either injecting Arc antisense RNA into the hippocampus or knocking out the gene can prevent the maintenance of long-term memory and LTP (Guzowski et al., 2000 ; Plath et al., 2006) .
The most salient finding of the present study was that 24 h after withdrawal of PCP, Arc mRNA expression was found to be up-regulated in the CA1 region of the hippocampus and retrosplenial cortex. However, PCP treatment failed to induce Arc mRNA expression in basal ganglia or prefrontal cortex. These regional differences in Arc mRNA expression may be attributed to the region-specific interaction of PCP with multiple neurotransmitter systems, including glutamatergic, dopaminergic and serotonergic. The NMDARs have been primarily implicated in the mechanisms of action of PCP. However, previous studies have shown that NMDAR activation in the hippocampus induces Arc mRNA expression (Steward and Worley, 2001) , while the present results suggest that blockade of NMDARs by PCP may facilitate Arc expression in hippocampus and retrosplenial cortex. The NMDAR blockade may thus have distinct effects on Arc after repeated treatment with low doses of PCP and/or other neurotransmitter systems or factors may be involved. Interestingly, an acute high dose (10 mg/ kg) of PCP increased Arc mRNA levels in the prefrontal cortex, nucleus accumbens and posterior cingulate cortex (Nakahara et al., 2000) . This pattern of expression is different from that obtained in the present study. The discrepancy could be explained by different dose levels of PCP and/or procedure of treatment (i.e. acute vs. repeated).
In contrast to Arc, spinophilin, a protein that is highly enriched in dendritic spines was significantly decreased in the striatum in PCP-treated mice. This is of particular interest since spinophilin has been reported to modulate dendritic morphology and glutamatergic synaptic transmission (Feng et al., 2000) . Moreover, spinophilin mRNA has been shown to be altered in the hippocampus and thalamus of schizophrenia patients (Clinton et al., 2005 ; Law et al., 2004) . However, the potential implications of this abnormality are not clear. Although spine density is increased in spinophilin knockout mice, spine density returns to baseline when such animals mature (Feng et al., 2000) .
Conclusion
It has been difficult to identify in a precise manner how genetic and non-genetic factors are involved in the pathogenesis of schizophrenia. One major problem is the heterogeneity of representing symptoms, which indicate multiple structural and molecular mechanisms. The cognitive deficits seen in schizophrenia also involve multiple domains of functions probably involving heterogeneous mechanisms. Therefore, it will be critical to find out whether these deficits are selective for a specific circuitry within the cortex and hippocampus. The present results indicate that low doses of PCP in mice can produce long-term impairments in long-term and working memory in the water-maze task without any disturbances in sensorimotor functions. Treatment with PCP affected corticohippocampal circuitry with major effects in the CA1 region and the retrosplenial cortex in the expression of Arc. These areas are involved in processing of visuospatial information as well as in the processing of cortical sensory input (Burwell et al., 2004 ; Keene and Bucci, 2008) . In addition, striatal function was affected, indicated by a reduction in the expression of spinophilin, which is involved in plasticity-related processes at striatal dendritic spines.
These results suggest that the low-dose PCP model may have significant potential in characterizing the behavioural and molecular mechanisms underlying cognitive deficits seen in schizophrenia patients.
